Over last few decades, several human monoclonal antibodies (mAbs) have been licensed for the treatment of cancer, and autoimmune and inflammatory diseases. With the recent discovery and production of highly potent broadly neutralizing and other multifunctional antibodies to human immunodeficiency virus (HIV), mAbs are now being considered for HIV therapy and prophylaxis. Most HIV transmission events occur across genital or rectal mucosal surfaces following sexual intercourse with an HIV-infected partner.
With the introduction of new prevention and intervention strategies, the global HIV incidence has dropped gradually but this rate is still unacceptably high. Approximately, one-third of HIV-infected individuals make HIV neutralizing-antibodies, and B cells from these individuals were used to isolate the first generation HIV-neutralizing mAbs. However, these conserved epitopes shared…
